| Bioactivity | NW-1689 is a process-related impurity of safinamide mesilate (SAFM). SAFM is a drug used to treat Parkinson's disease (PD). It is a highly selective and reversible inhibitor of monoamine oxidase-B (MAO-B) and also blocks sodium and N-type calcium channels. These effects of SAFM help reduce the breakdown of dopamine and inhibit the release of glutamate. NW-1689 has a similar chemical structure to SAFM and has some similar pharmacological effects as SAFM, and can be used in Parkinson's disease research[1]. |
| CAS | 405-85-6 |
| Formula | C14H11FO3 |
| Molar Mass | 246.23 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zou L, et al. Identification, characterization, and quantification of impurities of safinamide mesilate: process-related impurities and degradation products[J]. Journal of AOAC International, 2017, 100(4): 1029-1037. |